KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Pacific Biosciences Of California (PACB) over the last 17 years, with Q3 2025 value amounting to $1.7 million.

  • Pacific Biosciences Of California's Net Cash Flow rose 10770.87% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.9 million, marking a year-over-year increase of 9289.18%. This contributed to the annual value of -$125.0 million for FY2024, which is 1416.62% up from last year.
  • Per Pacific Biosciences Of California's latest filing, its Net Cash Flow stood at $1.7 million for Q3 2025, which was up 10770.87% from -$4.1 million recorded in Q2 2025.
  • In the past 5 years, Pacific Biosciences Of California's Net Cash Flow registered a high of $850.8 million during Q1 2021, and its lowest value of -$473.6 million during Q2 2021.
  • Its 5-year average for Net Cash Flow is -$1.5 million, with a median of -$6.0 million in 2022.
  • In the last 5 years, Pacific Biosciences Of California's Net Cash Flow tumbled by 172029.21% in 2021 and then soared by 303348.3% in 2023.
  • Quarter analysis of 5 years shows Pacific Biosciences Of California's Net Cash Flow stood at $35.4 million in 2021, then tumbled by 41.6% to $20.7 million in 2022, then crashed by 1096.02% to -$205.7 million in 2023, then surged by 89.01% to -$22.6 million in 2024, then surged by 107.36% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, -$4.1 million for Q2 2025, and $3.1 million during Q1 2025.